|
Name |
[(3S,6R,7R)-3,7-dihydroxy-3-(3-hydroxypropyl)-7-methyl-8-oxo-1,4,5,6-tetrahydroisochromen-6-yl] 2,4-dihydroxy-6-methylbenzoate
|
| Molecular Formula | C21H26O9 | |
| IUPAC Name* |
[(3S,6R,7R)-3,7-dihydroxy-3-(3-hydroxypropyl)-7-methyl-8-oxo-1,4,5,6-tetrahydroisochromen-6-yl] 2,4-dihydroxy-6-methylbenzoate
|
|
| SMILES |
CC1=CC(=CC(=C1C(=O)O[C@@H]2CC3=C(CO[C@](C3)(CCCO)O)C(=O)[C@]2(C)O)O)O
|
|
| InChI |
InChI=1S/C21H26O9/c1-11-6-13(23)8-15(24)17(11)19(26)30-16-7-12-9-21(28,4-3-5-22)29-10-14(12)18(25)20(16,2)27/h6,8,16,22-24,27-28H,3-5,7,9-10H2,1-2H3/t16-,20-,21+/m1/s1
|
|
| InChIKey |
NTGQTBBYTOAJAQ-HBGVWJBISA-N
|
|
| Synonyms |
Montagnuphilone F; CHEMBL4066596; J3.616.325I
|
|
| CAS | NA | |
| PubChem CID | 132992081 | |
| ChEMBL ID | CHEMBL4066596 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 422.4 | ALogp: | 0.6 |
| HBD: | 5 | HBA: | 9 |
| Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 154.0 | Aromatic Rings: | 3 |
| Heavy Atoms: | 30 | QED Weighted: | 0.441 |
| Caco-2 Permeability: | -5.685 | MDCK Permeability: | 0.00002010 |
| Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.997 |
| Human Intestinal Absorption (HIA): | 0.866 | 20% Bioavailability (F20%): | 0.999 |
| 30% Bioavailability (F30%): | 0.992 |
| Blood-Brain-Barrier Penetration (BBB): | 0.209 | Plasma Protein Binding (PPB): | 71.92% |
| Volume Distribution (VD): | 1.645 | Fu: | 31.58% |
| CYP1A2-inhibitor: | 0.06 | CYP1A2-substrate: | 0.307 |
| CYP2C19-inhibitor: | 0.024 | CYP2C19-substrate: | 0.063 |
| CYP2C9-inhibitor: | 0.034 | CYP2C9-substrate: | 0.21 |
| CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.082 |
| CYP3A4-inhibitor: | 0.642 | CYP3A4-substrate: | 0.199 |
| Clearance (CL): | 8.359 | Half-life (T1/2): | 0.81 |
| hERG Blockers: | 0.02 | Human Hepatotoxicity (H-HT): | 0.072 |
| Drug-inuced Liver Injury (DILI): | 0.915 | AMES Toxicity: | 0.03 |
| Rat Oral Acute Toxicity: | 0.415 | Maximum Recommended Daily Dose: | 0.205 |
| Skin Sensitization: | 0.039 | Carcinogencity: | 0.711 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.036 |
| Respiratory Toxicity: | 0.927 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003450 | ![]() |
1.000 | D02GAC | ![]() |
0.254 | ||
| ENC003839 | ![]() |
0.822 | D08NQZ | ![]() |
0.250 | ||
| ENC003449 | ![]() |
0.822 | D0R6RC | ![]() |
0.246 | ||
| ENC003838 | ![]() |
0.822 | D07MGA | ![]() |
0.246 | ||
| ENC005503 | ![]() |
0.602 | D05AFR | ![]() |
0.243 | ||
| ENC002211 | ![]() |
0.569 | D0J2NK | ![]() |
0.237 | ||
| ENC002726 | ![]() |
0.539 | D04VEJ | ![]() |
0.233 | ||
| ENC003837 | ![]() |
0.528 | D07VLY | ![]() |
0.222 | ||
| ENC002132 | ![]() |
0.500 | D0C9XJ | ![]() |
0.222 | ||
| ENC002131 | ![]() |
0.441 | D0L7AS | ![]() |
0.220 | ||